Antibiotics treatment promotes vasculogenesis in the brain of glioma-bearing mice

Rosito, Maria; Maqbool, Javeria; Reccagni, Alice; Giampaoli, Ottavia; Sciubba, Fabio; Antonangeli, Fabrizio; Scavizzi, Ferdinando; Raspa, Marcello; Cordella, Federica; Tondo, Lucrezia; Di Angelantonio, Silvia; Trettel, Flavia; Miccheli, Alfredo; D’Alessandro, Giuseppina; Limatola, Cristina

doi:10.1038/s41419-024-06578-w

Cited by 5 publications

(2 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These two groups differed significantly in steroid and tryptophan metabolic pathways, as well as in macrophage and cytotoxic T lymphocyte infiltration [ 10 ]. Previous research has indicated that broad-spectrum antibiotic cocktail (ABX) therapy can lead to tumor-promoting effects by reducing cytotoxic NK cell subsets and impairing microglial function in the intracranial tumor microenvironment [ 100 , 134 ]. These findings are consistent with the results of the aforementioned studies, highlighting the crucial role of the intestinal flora as a target for sensitizing chemotherapeutic agents.…”

Section: Gut Bacteria and Cns Tumorsmentioning

confidence: 99%

The Role of Bacteria in Central Nervous System Tumors: Opportunities and Challenges

Zhang,

Li,

Zhang

2024

Microorganisms

View full text Add to dashboard Cite

Tumors of the central nervous system (CNS) are severe and refractory diseases with poor prognosis, especially for patients with malignant glioblastoma and brain metastases. Currently, numerous studies have explored the potential role of bacteria and intestinal flora in tumor development and treatment. Bacteria can penetrate the blood–brain barrier (BBB), targeting the hypoxic microenvironment at the core of tumors, thereby eliminating tumors and activating both the innate and adaptive immune responses, rendering them promising therapeutic agents for CNS tumors. In addition, engineered bacteria and derivatives, such as bacterial membrane proteins and bacterial spores, can also be used as good candidate carriers for targeted drug delivery. Moreover, the intestinal flora can regulate CNS tumor metabolism and influence the immune microenvironment through the “gut–brain axis”. Therefore, bacterial anti-tumor therapy, engineered bacterial targeted drug delivery, and intervention of the intestinal flora provide therapeutic modalities for the treatment of CNS tumors. In this paper, we performed a comprehensive review of the mechanisms and therapeutic practices of bacterial therapy for CNS tumors and discussed potential future research directions in this field.

show abstract

Section: Gut Bacteria and Cns Tumorsmentioning

confidence: 99%

The Role of Bacteria in Central Nervous System Tumors: Opportunities and Challenges

Zhang,

Li,

Zhang

2024

Microorganisms

View full text Add to dashboard Cite

show abstract

“…The efficacy and toxicity of chemotherapy drugs such as temozolomide may be influenced by gut microbiota metabolism ( 76 ). However, predicting and regulating these interactions to optimize drug efficacy and reduce side effects remains challenging, especially in GBM where patients typically require multiple drug combinations, increasing the complexity of drug microbiota interactions ( 77 ).…”

Section: Dilemma Of the Gut Microbiota In The Treatment Of Gbmmentioning

confidence: 99%

Role of gut microbiota in regulating immune checkpoint inhibitor therapy for glioblastoma

Zhang,

Hong,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Glioblastoma (GBM) is a highly malignant, invasive, and poorly prognosed brain tumor. Unfortunately, active comprehensive treatment does not significantly prolong patient survival. With the deepening of research, it has been found that gut microbiota plays a certain role in GBM, and can directly or indirectly affect the efficacy of immune checkpoint inhibitors (ICIs) in various ways. (1) The metabolites produced by gut microbiota directly affect the host’s immune homeostasis, and these metabolites can affect the function and distribution of immune cells, promote or inhibit inflammatory responses, affect the phenotype, angiogenesis, inflammatory response, and immune cell infiltration of GBM cells, thereby affecting the effectiveness of ICIs. (2) Some members of the gut microbiota may reverse T cell function inhibition, increase T cell anti-tumor activity, and ultimately improve the efficacy of ICIs by targeting specific immunosuppressive metabolites and cytokines. (3) Some members of the gut microbiota directly participate in the metabolic process of drugs, which can degrade, transform, or produce metabolites, affecting the effective concentration and bioavailability of drugs. Optimizing the structure of the gut microbiota may help improve the efficacy of ICIs. (4) The gut microbiota can also regulate immune cell function and inflammatory status in the brain through gut brain axis communication, indirectly affecting the progression of GBM and the therapeutic response to ICIs. (5) Given the importance of gut microbiota for ICI therapy, researchers have begun exploring the use of fecal microbiota transplantation (FMT) to transplant healthy or optimized gut microbiota to GBM patients, in order to improve their immune status and enhance their response to ICI therapy. Preliminary studies suggest that FMT may enhance the efficacy of ICI therapy in some patients. In summary, gut microbiota plays a crucial role in regulating ICIs in GBM, and with a deeper understanding of the relationship between gut microbiota and tumor immunity, it is expected to develop more precise and effective personalized ICI therapy strategies for GBM, in order to improve patient prognosis.

show abstract

Enhancing cancer immunotherapy and antiangiogenic therapy by regulating gut microbes: Opportunities and challenges

Xu,

Tian,

et al. 2024

MedComm – Oncology

View full text Add to dashboard Cite

As the largest microecosystem in the human body, gut microbes (GMs) and their metabolites play an important role in regulating human health. In recent years, immune checkpoint therapy (ICT) combined with antiangiogenic agents is an emerging combination therapy for cancer. There is growing evidence that GMs can affect the effectiveness of drugs to treat cancer. GMs not only regulate angiogenesis in the tumor microenvironment, but also influence the efficacy of immune checkpoint inhibitors. Many studies show that Bifidobacterium can upregulate the anticancer function of immune checkpoint blockers. In addition, GMs have been found to be involved in the formation of blood vessels and other developmental processes. Clinically, GMs are believed to play a key role in patients receiving antiangiogenic therapy and ICT. In this perspective, we provide an overview of the composition and function of the gut microbiome, and discuss the role of the GMs against the conditioning of angiogenic therapy and ICT. We also summarize new approaches and clinical translational trials using GMs for cancer therapy, and present opportunities and challenges for targeting GMs for cancer therapy in the future.

show abstract

Antibiotics treatment promotes vasculogenesis in the brain of glioma-bearing mice

Cited by 5 publications

References 94 publications

The Role of Bacteria in Central Nervous System Tumors: Opportunities and Challenges

The Role of Bacteria in Central Nervous System Tumors: Opportunities and Challenges

Role of gut microbiota in regulating immune checkpoint inhibitor therapy for glioblastoma

Enhancing cancer immunotherapy and antiangiogenic therapy by regulating gut microbes: Opportunities and challenges

Contact Info

Product

Resources

About